Completing data — refresh the page later to see the latest
1204918-72-8CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1VXBAJLGYBMTJCY-NSCUHMNNSA-NZotiraciclib is under investigation in clinical trial NCT02942264 (Zotiraciclib (TG02) Plus Dose-dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma).
1204918-72-8DTXSID601337151CHEMBL1944698Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
UsesTG 02 is a cyclin dependent kinase inhibitors (CDK inhibitors) for the treatment of chronic lymphocytic leukemia.